Ryan D Maynard's most recent trade in Iovance Biotherapeutics Inc was a trade of 50,000 Common Stock done at an average price of $10.1 . Disclosure was reported to the exchange on Nov. 12, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics Inc | Ryan D. Maynard | Director | Sale of securities on an exchange or to another person at price $ 10.06 per share. | 12 Nov 2024 | 50,000 | 7,500 (0%) | 0% | 10.1 | 503,000 | Common Stock |
| Iovance Biotherapeutics Inc | Ryan D. Maynard | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2024 | 50,000 | 0 | - | - | Stock Option (right to buy) | |
| Iovance Biotherapeutics Inc | Ryan D. Maynard | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.45 per share. | 12 Nov 2024 | 50,000 | 57,500 (0%) | 0% | 7.5 | 372,500 | Common Stock |
| Iovance Biotherapeutics Inc | Ryan D. Maynard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 49,303 | 49,303 | - | - | Deferred Restricted Stock Unit | |
| Iovance Biotherapeutics Inc | Ryan D. Maynard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 50,000 | 50,000 | - | - | Deferred Restricted Stock Unit | |
| Tvardi Therapeutics Inc. | D. Ryan Maynard | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 0.53 per share. | 08 Feb 2024 | 5,488 | 8,012 (0%) | 0% | 0.5 | 2,909 | Common Stock |
| Tvardi Therapeutics Inc. | Ryan Maynard D. | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 13,500 | 13,500 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Ryan D. Maynard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 51,955 | 51,955 | - | - | Deferred Restricted Stock Unit | |
| Tvardi Therapeutics Inc. | Ryan D. Maynard | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 81,000 | 81,000 | - | - | Stock Option (Right to Buy) | |
| Tvardi Therapeutics Inc. | Ryan D. Maynard | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2022 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Iovance Biotherapeutics Inc | Ryan D. Maynard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 51,204 | 51,204 | - | - | Deferred Restricted Stock Unit | |
| Iovance Biotherapeutics Inc | Ryan D. Maynard | Director | Purchase of securities on an exchange or from another person at price $ 6.75 per share. | 31 May 2022 | 7,500 | 7,500 (0%) | 0% | 6.7 | 50,588 | Common Stock |
| Iovance Biotherapeutics Inc | Ryan D. Maynard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 35,000 | 35,000 | - | - | Stock Option (right to buy) |